Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)-Reference-Cited by-同舟云学术

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Published:2021-01 Issue:1 Volume:32 Page:49-57
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fasching P.A.,Link T.,Hauke J.,Seither F.,Jackisch C.,Klare P.,Schmatloch S.,Hanusch C.,Huober J.,Stefek A.,Seiler S.,Schmitt W.D.,Uleer C.,Doering G.,Rhiem K.,Schneeweiss A.,Engels K.,Denkert C.,Schmutzler R.K.,Hahnen E.,Untch M.,Burchardi N.,Blohmer J.-U.,Loibl S.

Funder

Myriad Genetics

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference29 articles.

1. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?;Pellegrino;ESMO Open,2019

2. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomised clinical trial;Hahnen;JAMA Oncol,2017

3. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomised clinical trial;Pohl-Rescigno;JAMA Oncol,2020

4. BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study;Fasching;J Clin Oncol,2018

5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial;Loibl;Lancet Oncol,2018

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?;npj Breast Cancer;2024-09-05

2. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

3. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

4. Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis;Frontiers in Immunology;2024-08-23

5. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15